NASDAQ:EIGR - Eiger BioPharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 205.62 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.18
▲ +0.15 (1.87%)
1 month | 3 months | 12 months
Get New Eiger BioPharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EIGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EIGR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.00
▲ +205.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eiger BioPharmaceuticals in the last 3 months. The average price target is $25.00, with a high forecast of $28.00 and a low forecast of $22.00. The average price target represents a 205.62% upside from the last price of $8.18.
Buy
The current consensus among 2 investment analysts is to buy stock in Eiger BioPharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2021WedbushReiterated RatingBuy$22.00Medium
i
Rating by Liana Moussatos at Wedbush
9/29/2020LADENBURG THALM/SH SHReiterated RatingBuy$28.00Medium
i
9/1/2020WedbushReiterated RatingBuy$32.00High
i
Rating by Liana Moussatos at Wedbush
6/4/2020WedbushReiterated RatingBuy$34.00High
i
Rating by L. Moussatos at Wedbush
4/3/2020WedbushReiterated RatingBuy$35.00 ➝ $33.00High
i
Rating by L. Moussatos at Wedbush
3/24/2020WedbushReiterated RatingOutperformMedium
i
Rating by L. Moussatos at Wedbush
1/22/2020LADENBURG THALM/SH SHBoost Price TargetBuy$28.00 ➝ $31.00Low
i
1/6/2020WedbushReiterated RatingBuy$35.00Low
i
12/16/2019Gilford SecuritiesInitiated CoverageAverageMedium
i
11/11/2019LADENBURG THALM/SH SHReiterated RatingBuy$28.00High
i
8/12/2019LADENBURG THALM/SH SHReiterated RatingBuy$28.00High
i
6/26/2019KeyCorpInitiated CoverageOverweight$22.00 ➝ $10.72Low
i
6/26/2019CitigroupInitiated CoverageBuy$22.00 ➝ $22.00Low
i
6/18/2019WedbushReiterated RatingOutperform$35.00Low
i
Rating by Liana Moussatos at Wedbush
6/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$28.00High
i
5/16/2019WedbushReiterated RatingBuy$35.00Low
i
Rating by Liana Moussatos at Wedbush
4/24/2019WedbushLower Price TargetOutperform$43.00 ➝ $35.00Low
i
Rating by Liana Moussatos at Wedbush
4/12/2019WedbushSet Price TargetBuy$43.00High
i
Rating by Liana Moussatos at Wedbush
3/26/2019WedbushReiterated RatingBuy$43.00Low
i
Rating by Liana Moussatos at Wedbush
3/19/2019WedbushSet Price TargetBuy$43.00Medium
i
Rating by Liana Moussatos at Wedbush
2/19/2019WedbushReiterated RatingBuy$43.00Low
i
Rating by Liana Moussatos at Wedbush
1/28/2019Robert W. BairdInitiated CoverageOutperform$47.00Medium
i
12/19/2018BTIG ResearchBoost Price TargetBuy$44.00 ➝ $47.00High
i
10/19/2018WedbushSet Price TargetBuy$55.00Low
i
Rating by Liana Moussatos at Wedbush
10/18/2018OppenheimerSet Price TargetBuy$26.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/17/2018LADENBURG THALM/SH SHSet Price TargetBuy$28.00High
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
9/10/2018WedbushSet Price TargetBuy$53.00Low
i
Rating by Liana Moussatos at Wedbush
8/14/2018OppenheimerSet Price TargetBuy$26.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/13/2018WedbushSet Price TargetBuy$53.00Low
i
Rating by Liana Moussatos at Wedbush
5/30/2018Piper Jaffray CompaniesReiterated RatingOverweight$24.00Low
i
5/18/2018Piper Jaffray CompaniesBoost Price TargetOverweight$28.00High
i
5/17/2018OppenheimerSet Price TargetBuy$26.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/17/2018BTIG ResearchBoost Price TargetBuy ➝ Buy$23.00 ➝ $39.00High
i
5/17/2018WedbushReiterated RatingOutperform$53.00 ➝ $36.00High
i
5/11/2018OppenheimerSet Price TargetBuy$26.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/9/2018B. RileyInitiated CoverageBuy ➝ Buy$24.00High
i
Rating by M. Kumar at B. Riley
4/26/2018WedbushReiterated RatingOutperform$36.00Medium
i
3/22/2018WedbushLower Price TargetOutperform$36.00 ➝ $34.00High
i
3/21/2018OppenheimerReiterated RatingBuyHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/12/2018OppenheimerSet Price TargetBuy$26.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/16/2018OppenheimerSet Price TargetBuy$26.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/16/2018Piper Jaffray CompaniesReiterated RatingOverweight$35.00 ➝ $17.00High
i
1/3/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$32.00High
i
12/7/2017OppenheimerSet Price TargetBuy$34.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/25/2017WedbushReiterated RatingBuyN/A
i
Rating by L. Moussatos at Wedbush
10/23/2017OppenheimerSet Price TargetBuy$34.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/19/2017Roth CapitalInitiated CoverageBuy ➝ Buy$35.00N/A
i
Rating by M. Higgins at Roth Capital
9/25/2017OppenheimerReiterated RatingBuy$34.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/15/2017Piper Jaffray CompaniesReiterated RatingBuy$36.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/14/2017WedbushReiterated RatingOurperform$34.00Low
i
Rating by L. Moussatos at Wedbush
7/14/2017BTIG ResearchInitiated CoverageBuy$32.00High
i
6/21/2017WedbushReiterated RatingOutperform$28.00 ➝ $34.00High
i
Rating by L. Moussatos at Wedbush
6/8/2017OppenheimerSet Price TargetBuy$34.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/15/2017Jefferies Financial GroupReiterated RatingBuy$28.00 ➝ $27.00Medium
i
5/10/2017OppenheimerSet Price TargetBuy$34.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/22/2017OppenheimerSet Price TargetBuy$34.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/8/2017OppenheimerSet Price TargetBuy$34.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/8/2017Piper Jaffray CompaniesSet Price TargetBuy$36.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
4/7/2017Jefferies Financial GroupReiterated RatingBuy$28.00High
i
3/24/2017Jefferies Financial GroupReiterated RatingBuyLow
i
1/11/2017OppenheimerSet Price TargetBuy$34.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/11/2016OppenheimerSet Price TargetBuy$34.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/1/2016OppenheimerSet Price TargetBuy$34.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/21/2016OppenheimerReiterated RatingOutperform$34.00N/A
i
11/8/2016WedbushReiterated RatingOutperform$34.00 ➝ $36.00N/A
i
Rating by Heather Behanna at Wedbush
10/20/2016Jefferies Financial GroupReiterated RatingBuy$33.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
8/11/2016WedbushReiterated RatingOutperform$36.00N/A
i
Rating by Heather Behanna at Wedbush
7/5/2016OppenheimerInitiated CoverageOutperform$34.00N/A
i
6/13/2016WedbushReiterated RatingBuy$36.00N/A
i
Rating by Heather Behanna at Wedbush
6/1/2016WedbushInitiated CoverageOutperform$36.00N/A
i
Rating by H. Behanna at Wedbush
5/16/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
4/21/2016Piper Jaffray CompaniesReiterated RatingBuy$30.00 ➝ $33.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
(Data available from 4/21/2016 forward)
Eiger BioPharmaceuticals logo
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $8.18
$7.85
$8.20

50 Day Range

MA: $9.09
$8.03
$10.47

52 Week Range

Now: $8.18
$6.76
$13.99

Volume

163,511 shs

Average Volume

258,468 shs

Market Capitalization

$277.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Eiger BioPharmaceuticals?

The following sell-side analysts have issued research reports on Eiger BioPharmaceuticals in the last twelve months: LADENBURG THALM/SH SH, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for EIGR.

What is the current price target for Eiger BioPharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Eiger BioPharmaceuticals in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 205.6%. LADENBURG THALM/SH SH has the highest price target set, predicting EIGR will reach $28.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $22.00 for Eiger BioPharmaceuticals in the next year.
View the latest price targets for EIGR.

What is the current consensus analyst rating for Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EIGR will outperform the market and that investors should add to their positions of Eiger BioPharmaceuticals.
View the latest ratings for EIGR.

What other companies compete with Eiger BioPharmaceuticals?

How do I contact Eiger BioPharmaceuticals' investor relations team?

Eiger BioPharmaceuticals' physical mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company's listed phone number is 650-272-6138 and its investor relations email address is [email protected] The official website for Eiger BioPharmaceuticals is www.eigerbio.com.